President and CEO
Mr. Ferrara was most recently Founder, President and CEO of NeuroVia, Inc., a clinical stage orphan CNS disease company, where he raised a Series A financing, built an efficient team and established the clinical and regulatory strategy to lead the company into an efficacy study. Previously, he was at the Novartis Venture Fund (NVF), where he founded NeuroVia in 2013 amongst his other activities as an operating partner. He joined NVF from portfolio company Sorbent Therapeutics where he was consulting Chief Business Officer, raising $58M in financing and leading the refocusing of the company’s lead program. Prior roles include General Partner and Managing Director at Burrill & Company, after beginning his venture capital and business development career at GeneChem Management. In addition to his investing responsibilities at GeneChem, he was part of the business development team at BiocChem Pharma and held operating positions in portfolio companies, including CEO of Targanta Therapeutics. He received his MBA and MSc from McGill University.
Michael Zdanowski, MBA
Senior Vice President, Biopharmaceutical Operations
Michael Zdanowski joined Medeor in March 2018 and is responsible for development, manufacturing and quality control for all Medeor products. Dr. Zdanowski brings 20+ years of GMP operations and manufacturing experience to Medeor’s novel Hematopoietic/T-Cell therapy product platform. Previously, he served as Vice President of GMP Operations at the New York Stem Cell Foundation, Vice President of Manufacturing at Mesoblast LTD, and Director of Operations of the National Cord Blood Program at the New York Blood Center. While there, he led the team in the preparation and submission of the first successful biologics license application for an allogeneic cell therapy product.
Mr. Zdanowski received his BS in mechanical engineering, and his BA in philosophy from the University of Pennsylvania, and his MBA from Columbia University.
Suzanne Crowley, MS-CROM
Vice President, Clinical Operations
Suzanne (Sue) Crowley joined the Company in March 2019, and is responsible for all Medeor Clinical Operations. Previously she was at Swedish Orphan Biovitrum AB, North America between 2011 and 2019, where she served in several positions of increasing responsibility including Associate Director of Strategy and Director of Medical Affairs Operations. She also served as the president of her own consulting company between 2010 and 2014. She previously worked at Genzyme Transplant and 0ncology between 2003 and 2010, where she was the Director of External Research/Director of Global Pre-clinical ISS Program Transplant/Oncology. Before joining Genzyme, she was a Medical Science Liaison for SangStat, between 1999 and 2003.
Ms. Crowley is a nurse practitioner and received her BSN from Syracuse University and her MS-CROM from Drexel University, College of Medicine.